Details:
9MW3011 is an anti-TMPRSS6 antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding. It is being evaluated for the treatment of β-thalassemia and polycythemia vera.
Lead Product(s): 9MW3011
Therapeutic Area: Genetic Disease Product Name: DISC-3405
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Disc medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
9MW3011 is monoclonal antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding, inhibit the absorption and release of iron, and lower the serum iron level, thus regulating the iron homeostasis in vivo.
Lead Product(s): 9MW3011
Therapeutic Area: Genetic Disease Product Name: 9MW3011
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Under the agreement, both parties will develop hematopoietic stem cell regenerative therapies, ET-01, including the development of genetically-modified hematopoietic stem cell therapies and exploration of novel biomarkers to optimize quality control for stem cell production.
Lead Product(s): ET-01
Therapeutic Area: Genetic Disease Product Name: ET-01
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Haihe Laboratory
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 24, 2022